Shield Therapeutics PLC (GB:STX)
LSE:STX
Holding GB:STX?
Track your performance easily

Shield Therapeutics (STX) Financial Statements

17 Followers

Shield Therapeutics Financial Overview

Shield Therapeutics's market cap is currently ―. The company's EPS TTM is p-0.038; its P/E ratio is -0.74; Shield Therapeutics is scheduled to report earnings on April 24, 2025, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Dec 21Jun 21Dec 20Jun 20
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments£ 2.40M£ 12.12M£ 22.60M£ 2.94M£ 6.51M
Total Assets£ 35.82M£ 44.41M£ 52.41M£ 32.53M£ 38.24M
Total Debt£ 0.00£ 156.00K£ 0.00£ 28.00K£ 0.00
Net Debt£ -2.40M£ -11.96M£ -22.60M£ -2.91M£ -6.51M
Total Liabilities£ 3.25M£ 3.38M£ 1.39M£ 2.25M£ 2.77M
Stockholders Equity£ 32.57M£ 41.03M£ 51.01M£ 30.28M£ 35.47M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in GBP

Shield Therapeutics Earnings and Revenue History

Shield Therapeutics Debt to Assets

Shield Therapeutics Cash Flow

Shield Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis